206 related articles for article (PubMed ID: 24072101)
1. MicroRNA expression at diagnosis adds relevant prognostic information to molecular categorization in patients with intermediate-risk cytogenetic acute myeloid leukemia.
Díaz-Beyá M; Brunet S; Nomdedéu J; Tejero R; Díaz T; Pratcorona M; Tormo M; Ribera JM; Escoda L; Duarte R; Gallardo D; Heras I; Queipo de Llano MP; Bargay J; Monzo M; Sierra J; Navarro A; Esteve J;
Leukemia; 2014 Apr; 28(4):804-12. PubMed ID: 24072101
[TBL] [Abstract][Full Text] [Related]
2. The lincRNA HOTAIRM1, located in the HOXA genomic region, is expressed in acute myeloid leukemia, impacts prognosis in patients in the intermediate-risk cytogenetic category, and is associated with a distinctive microRNA signature.
Díaz-Beyá M; Brunet S; Nomdedéu J; Pratcorona M; Cordeiro A; Gallardo D; Escoda L; Tormo M; Heras I; Ribera JM; Duarte R; de Llano MP; Bargay J; Sampol A; Nomdedeu M; Risueño RM; Hoyos M; Sierra J; Monzo M; Navarro A; Esteve J;
Oncotarget; 2015 Oct; 6(31):31613-27. PubMed ID: 26436590
[TBL] [Abstract][Full Text] [Related]
3. The expression level of BAALC-associated microRNA miR-3151 is an independent prognostic factor in younger patients with cytogenetic intermediate-risk acute myeloid leukemia.
Díaz-Beyá M; Brunet S; Nomdedéu J; Cordeiro A; Tormo M; Escoda L; Ribera JM; Arnan M; Heras I; Gallardo D; Bargay J; Queipo de Llano MP; Salamero O; Martí JM; Sampol A; Pedro C; Hoyos M; Pratcorona M; Castellano JJ; Nomdedeu M; Risueño RM; Sierra J; Monzó M; Navarro A; Esteve J
Blood Cancer J; 2015 Oct; 5(10):e352. PubMed ID: 26430723
[TBL] [Abstract][Full Text] [Related]
4. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
5. Differentially expressed miRNAs in cytogenetic and molecular subtypes of pediatric acute myeloid leukemia.
Danen-van Oorschot AA; Kuipers JE; Arentsen-Peters S; Schotte D; de Haas V; Trka J; Baruchel A; Reinhardt D; Pieters R; Zwaan CM; van den Heuvel-Eibrink MM
Pediatr Blood Cancer; 2012 May; 58(5):715-21. PubMed ID: 21818844
[TBL] [Abstract][Full Text] [Related]
6. Identification of let-7a-2-3p or/and miR-188-5p as prognostic biomarkers in cytogenetically normal acute myeloid leukemia.
Jinlong S; Lin F; Yonghui L; Li Y; Weidong W
PLoS One; 2015; 10(2):e0118099. PubMed ID: 25646775
[TBL] [Abstract][Full Text] [Related]
7. TET2 mutations improve the new European LeukemiaNet risk classification of acute myeloid leukemia: a Cancer and Leukemia Group B study.
Metzeler KH; Maharry K; Radmacher MD; Mrózek K; Margeson D; Becker H; Curfman J; Holland KB; Schwind S; Whitman SP; Wu YZ; Blum W; Powell BL; Carter TH; Wetzler M; Moore JO; Kolitz JE; Baer MR; Carroll AJ; Larson RA; Caligiuri MA; Marcucci G; Bloomfield CD
J Clin Oncol; 2011 Apr; 29(10):1373-81. PubMed ID: 21343549
[TBL] [Abstract][Full Text] [Related]
8. CEBPA single mutation can be a possible favorable prognostic indicator in NPM1 and FLT3-ITD wild-type acute myeloid leukemia patients with intermediate cytogenetic risk.
Park SH; Chi HS; Cho YU; Jang S; Park CJ
Leuk Res; 2013 Nov; 37(11):1488-94. PubMed ID: 24054719
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of miR-29a expression in pediatric acute myeloid leukemia.
Zhu C; Wang Y; Kuai W; Sun X; Chen H; Hong Z
Clin Biochem; 2013 Jan; 46(1-2):49-53. PubMed ID: 22981932
[TBL] [Abstract][Full Text] [Related]
10. Identification of the key genes and microRNAs in adult acute myeloid leukemia with FLT3 mutation by bioinformatics analysis.
Chen S; Chen Y; Zhu Z; Tan H; Lu J; Qin P; Xu L
Int J Med Sci; 2020; 17(9):1269-1280. PubMed ID: 32547322
[No Abstract] [Full Text] [Related]
11. miR-133a and miR-135a Regulate All-Trans Retinoic Acid-Mediated Differentiation in Pediatric Acute Myeloid Leukemia by Inhibiting CDX2 Translation and Serve as Prognostic Biomarkers.
Cheng YC; Fan Z; Liang C; Peng CJ; Li Y; Wang LN; Luo JS; Zhang XL; Liu Y; Zhang LD
Technol Cancer Res Treat; 2024; 23():15330338241248576. PubMed ID: 38693824
[No Abstract] [Full Text] [Related]
12. Differential expression of specific microRNA and their targets in acute myeloid leukemia.
Cammarata G; Augugliaro L; Salemi D; Agueli C; La Rosa M; Dagnino L; Civiletto G; Messana F; Marfia A; Bica MG; Cascio L; Floridia PM; Mineo AM; Russo M; Fabbiano F; Santoro A
Am J Hematol; 2010 May; 85(5):331-9. PubMed ID: 20425795
[TBL] [Abstract][Full Text] [Related]
13. Upregulation of microRNA-375 is associated with poor prognosis in pediatric acute myeloid leukemia.
Wang Z; Hong Z; Gao F; Feng W
Mol Cell Biochem; 2013 Nov; 383(1-2):59-65. PubMed ID: 23864342
[TBL] [Abstract][Full Text] [Related]
14. Distinctive microRNA signature of acute myeloid leukemia bearing cytoplasmic mutated nucleophosmin.
Garzon R; Garofalo M; Martelli MP; Briesewitz R; Wang L; Fernandez-Cymering C; Volinia S; Liu CG; Schnittger S; Haferlach T; Liso A; Diverio D; Mancini M; Meloni G; Foa R; Martelli MF; Mecucci C; Croce CM; Falini B
Proc Natl Acad Sci U S A; 2008 Mar; 105(10):3945-50. PubMed ID: 18308931
[TBL] [Abstract][Full Text] [Related]
15. The prognostic relevance of miR-212 expression with survival in cytogenetically and molecularly heterogeneous AML.
Sun SM; Rockova V; Bullinger L; Dijkstra MK; Döhner H; Löwenberg B; Jongen-Lavrencic M
Leukemia; 2013 Jan; 27(1):100-6. PubMed ID: 22692398
[TBL] [Abstract][Full Text] [Related]
16. Survival differences and associated molecular signatures of DNMT3A-mutant acute myeloid leukemia patients.
Lauber C; Correia N; Trumpp A; Rieger MA; Dolnik A; Bullinger L; Roeder I; Seifert M
Sci Rep; 2020 Jul; 10(1):12761. PubMed ID: 32728112
[TBL] [Abstract][Full Text] [Related]
17. Risk assessment in patients with acute myeloid leukemia and a normal karyotype.
Bienz M; Ludwig M; Leibundgut EO; Mueller BU; Ratschiller D; Solenthaler M; Fey MF; Pabst T
Clin Cancer Res; 2005 Feb; 11(4):1416-24. PubMed ID: 15746041
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of expression of a single microRNA, miR-181a, in cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.
Schwind S; Maharry K; Radmacher MD; Mrózek K; Holland KB; Margeson D; Whitman SP; Hickey C; Becker H; Metzeler KH; Paschka P; Baldus CD; Liu S; Garzon R; Powell BL; Kolitz JE; Carroll AJ; Caligiuri MA; Larson RA; Marcucci G; Bloomfield CD
J Clin Oncol; 2010 Dec; 28(36):5257-64. PubMed ID: 21079133
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of CEBPA mutations in a large cohort of younger adult patients with acute myeloid leukemia: impact of double CEBPA mutations and the interaction with FLT3 and NPM1 mutations.
Green CL; Koo KK; Hills RK; Burnett AK; Linch DC; Gale RE
J Clin Oncol; 2010 Jun; 28(16):2739-47. PubMed ID: 20439648
[TBL] [Abstract][Full Text] [Related]
20. Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia.
Bhayadia R; Krowiorz K; Haetscher N; Jammal R; Emmrich S; Obulkasim A; Fiedler J; Schwarzer A; Rouhi A; Heuser M; Wingert S; Bothur S; Döhner K; Mätzig T; Ng M; Reinhardt D; Döhner H; Zwaan CM; van den Heuvel Eibrink M; Heckl D; Fornerod M; Thum T; Humphries RK; Rieger MA; Kuchenbauer F; Klusmann JH
J Clin Oncol; 2018 Apr; 36(10):1007-1016. PubMed ID: 29432078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]